CASI Pharmaceuticals, Inc. (CASI)

2,3000 -0,1400 (-5,74%) Alla chiusura: 04:00PM EDT

CASI Pharmaceuticals, Inc.

1701-1702, China Central Office Tower 1
No. 81 Jianguo Road Chaoyang District
Beijing 100025
China
86 10 6508 6063
https://www.casipharmaceuticals.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 176

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Wei-Wu He Ph.D.	Chairman & CEO	565,36k	N/D	1965
Dr. Wei Zhang Ph.D.	President	1,13M	N/D	1960
Dr. Alexander A. Zukiwski M.D.	Executive VP & Chief Medical Officer	514,79k	N/D	1957
Ms. Kun Qian	VP & Global Controller	N/D	N/D	1982
Ms. Chunhua Wang	Chief Operating Officer	N/D	N/D	1972
Ms. Wei Gao	General Counsel	N/D	N/D	1981
Dr. James E. Goldschmidt Ph.D.	Chief Business Development Officer	N/D	N/D	N/D
Mr. Hai Huang	Global Chief Commercial Officer	N/D	N/D	1969
Ms. Amanda Cui	VP & Global Controller	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Governance aziendale

L'ISS Governance QualityScore di CASI Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.